Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056

The mGluR theory of fragile X mental retardation

Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580

Absence of expression of the FMR-1 gene in fragile X syndrome

Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S. T., Oostra, B. A., Caskey, C. T., & Nelson, D. L. (1991) · Cell · doi:10.1016/0092-8674(91)90125-i · Cited by 1,476

Varieties of Repetitive Behavior in Autism: Comparisons to Mental Retardation

Bodfish, J. W., Symons, F. J., Parker, D. E., & Lewis, M. H. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005596502855 · Cited by 1,223

Correction of Fragile X Syndrome in Mice

Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979

DNA methylation represses FMR-1 transcription in fragile X syndrome

Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe, D., & Warren, S. T. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.6.397 · Cited by 680

The Fragile X Syndrome Protein FMRP Associates with BC1 RNA and Regulates the Translation of Specific mRNAs at Synapses

Zalfa, F., Giorgi, M., Primerano, B., Moro, A., Di Penta, A., Reis, S., Oostra, B., & Bagni, C. (2003) · Cell · doi:10.1016/s0092-8674(03)00079-5 · Cited by 676

Advances in the Treatment of Fragile X Syndrome

Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596

Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP

Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.004 · Cited by 521

Pharmacological Rescue of Synaptic Plasticity, Courtship Behavior, and Mushroom Body Defects in a Drosophila Model of Fragile X Syndrome

McBride, S. M. J., Choi, C. H., Wang, Y., Liebelt, D. A., Braunstein, E. M., Ferreiro, D., Sehgal, A., Siwicki, K. K., Dockendorff, T. C., Nguyen, H. T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.038 · Cited by 484

Individual differences in reward responding explain placebo-induced expectations and effects

Scott, D. J., Stohler, C. S., Egnatuk, C. M., Wang, H., Koeppe, R. A., & Zubieta, J.-K. (2007) · Neuron · doi:10.1016/j.neuron.2007.06.028 · Cited by 466

Function and information content of DNA methylation

Schübeler, D. (2015) · Nature · doi:10.1038/nature14192 · Cited by 2,060

Far-red to near infrared analyte-responsive fluorescent probes based on organic fluorophore platforms for fluorescence imaging

Yuan, L., Lin, W., Zheng, K., He, L., & Huang, W. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35313j · Cited by 1,825

De Novo Gene Disruptions in Children on the Autistic Spectrum

Iossifov, I., Ronemus, M., Levy, D., Wang, Z., Hakker, I., Rosenbaum, J., Yamrom, B., Lee, Y.-H., Narzisi, G., Leotta, A., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.04.009 · Cited by 1,446

Advancing the understanding of autism disease mechanisms through genetics

de la Torre-Ubieta, L., Won, H., Stein, J. L., & Geschwind, D. H. (2016) · Nature Medicine · doi:10.1038/nm.4071 · Cited by 827

Fragile X syndrome

Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, F., Gantois, I., Sonenberg, N., Mandel, J. L., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.65 · Cited by 838

Synaptic Dysfunction in Neurodevelopmental Disorders Associated with Autism and Intellectual Disabilities

Zoghbi, H. Y., & Bear, M. F. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009886 · Cited by 797

Far-red and near infrared BODIPY dyes: synthesis and applications for fluorescent pH probes and bio-imaging

Ni, Y. Z., & Wu, J. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob42554a · Cited by 684

Bioinorganic Chemistry of Alzheimer’s Disease

Kepp, K. P. (2012) · Chemical Reviews · doi:10.1021/cr300009x · Cited by 683

Molecular Mechanisms of Fragile X Syndrome: A Twenty-Year Perspective

Santoro, M. R., Bray, S. M., & Warren, S. T. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132457 · Cited by 528

The oral microbiome in health and disease and the potential impact on personalized dental medicine

Zarco, M., Vess, T., & Ginsburg, G. (2011) · Oral Diseases · doi:10.1111/j.1601-0825.2011.01851.x · Cited by 521

The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy

McGeer, P. L., & McGeer, E. G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1177-7 · Cited by 467

The Genetic Landscapes of Autism Spectrum Disorders

Huguet, G., Ey, E., & Bourgeron, T. (2013) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091212-153431 · Cited by 486

The complexity of the Nrf2 pathway: beyond the antioxidant response

Huang, Y. S., Li, W., Su, Z., & Kong, A. T. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.08.001 · Cited by 460

α‐Defensins in human innate immunity

Lehrer, R. I., & Lu, W. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01082.x · Cited by 434

Intergenerational Influences on Child Growth and Undernutrition

Martorell, R., & Zongrone, A. A. (2012) · Paediatric and Perinatal Epidemiology · doi:10.1111/j.1365-3016.2012.01298.x · Cited by 416

Nanoplasmonic quantification of tumour-derived extracellular vesicles in plasma microsamples for diagnosis and treatment monitoring

Liang, K., Liu, F., Fan, J., Sun, D., Liu, C., Lyon, C. J., Bernard, D. W., Li, Y., Yokoi, K., Katz, M. H. G., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0021 · Cited by 373

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., Crawley, J. N., Curie, A., Des Portes, V., Hossain, F., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.221 · Cited by 336

Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours

Lee, B., Lee, K., Panda, S., Gonzales-Rojas, R., Chong, A., Bugay, V., Park, H. M., Brenner, R., Murthy, N., & Lee, H. Y. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0252-8 · Cited by 361

Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology

Howes, O. D., Rogdaki, M., Findon, J. L., Wichers, R. H., Charman, T., King, B. H., Loth, E., McAlonan, G. M., McCracken, J. T., Parr, J. R., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117741766 · Cited by 342

The Philadelphia Neurodevelopmental Cohort: A publicly available resource for the study of normal and abnormal brain development in youth

Satterthwaite, T. D., Connolly, J. J., Ruparel, K., Calkins, M. E., Jackson, C., Elliott, M. A., Roalf, D. R., Hopson, R., Prabhakaran, K., Behr, M., et al. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2015.03.056 · Cited by 335

Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases

Yan, Z., Gibson, S. A., Buckley, J. A., Qin, H., & Benveniste, E. N. (2018) · Clinical Immunology · doi:10.1016/j.clim.2016.09.014 · Cited by 318

Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics

Bagni, C., Tassone, F., Neri, G., & Hagerman, R. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63141 · Cited by 321

Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial

Berry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., Mu, Y., Nguyen, D. V., Gonzalez-Heydrich, J., Wang, P. P., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004214 · Cited by 328

Epigenetic Characterization of the FMR1 Gene and Aberrant Neurodevelopment in Human Induced Pluripotent Stem Cell Models of Fragile X Syndrome

Sheridan, S. D., Theriault, K. M., Reis, S. A., Zhou, F., Madison, J. M., Daheron, L. M., Loring, J. F., & Haggarty, S. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026203 · Cited by 313

FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States

Tassone, F., Iong, K. P., Tong, T., Lo, J., Gane, L. W., Berry‐Kravis, E., Nguyen, D. V., Mu, L. Y., Laffin, J. J. S., Bailey, D. B., et al. (2012) · Genome Medicine · doi:10.1186/gm401 · Cited by 321

Autism: A “Critical Period” Disorder?

LeBlanc, J. J., & Fagiolini, M. (2011) · Neural Plasticity · doi:10.1155/2011/921680 · Cited by 301

Fibronectin in development and wound healing

Patten, J., & Wang, K. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.09.005 · Cited by 317

A Randomized Double-Blind, Placebo-Controlled Trial of Minocycline in Children and Adolescents with Fragile X Syndrome

Leigh, M. J. S., Nguyen, D. V., Mu, Y., Winarni, T. I., Schneider, A., Chechi, T., Polussa, J., Doucet, P., Tassone, F., Rivera, S. M., et al. (2013) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e318287cd17 · Cited by 298

Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials

Berry-Kravis, E., Des Portes, V., Hagerman, R., Jacquemont, S., Charles, P., Visootsak, J., Brinkman, M., Rerat, K., Koumaras, B., Zhu, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aab4109 · Cited by 270

Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism

Silverman, J. L., Smith, D. G., Rizzo, S. J. S., Karras, M. N., Turner, S. M., Tolu, S. S., Bryce, D. K., Smith, D. L., Fonseca, K., Ring, R. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003501 · Cited by 251

Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?

Cohen, M. S., Smith, M. K., Muessig, K. E., Hallett, T. B., Powers, K. A., & Kashuba, A. D. M. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61998-4 · Cited by 257

Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome

Ronesi, J. A., Collins, K. A., Hays, S. A., Tsai, N.-P., Guo, W., Birnbaum, S. G., Hu, J.-H., Worley, P. F., Gibson, J. R., & Huber, K. M. (2012) · Nature Neuroscience · doi:10.1038/nn.3033 · Cited by 251

Reversal of Disease-Related Pathologies in the Fragile X Mouse Model by Selective Activation of GABA B Receptors with Arbaclofen

Henderson, C., Wijetunge, L., Kinoshita, M. N., Shumway, M., Hammond, R. S., Postma, F. R., Brynczka, C., Rush, R., Thomas, A., Paylor, R., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004218 · Cited by 249

Excitatory/inhibitory imbalance in autism spectrum disorders: Implications for interventions and therapeutics

Uzunova, G., Pallanti, S., & Hollander, E. (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1085597 · Cited by 257

Progress toward treatments for synaptic defects in autism

Delorme, R., Ey, E., Toro, R., Leboyer, M., Gillberg, C., & Bourgeron, T. (2013) · Nature Medicine · doi:10.1038/nm.3193 · Cited by 218

An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy

Millan, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.015 · Cited by 229

Development of allosteric modulators of GPCRs for treatment of CNS disorders

Nickols, H. H., & Conn, P. J. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.013 · Cited by 232

Hydrocarbons (jet fuel JP-8) induce epigenetic transgenerational inheritance of obesity, reproductive disease and sperm epimutations

Tracey, R., Manikkam, M., Guerrero‐Bosagna, C., & Skinner, M. K. (2013) · Reproductive Toxicology · doi:10.1016/j.reprotox.2012.11.011 · Cited by 226

Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome

Khwaja, O., Ho, E., Barnes, K. V., O’Leary, H. M., Pereira, L. M., Finkelstein, Y., Nelson, C. A., Vogel‐Farley, V. K., DeGregorio, G., Holm, I. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311141111 · Cited by 212

The Unstable Repeats—Three Evolving Faces of Neurological Disease

Nelson, D. L., Orr, H. T., & Warren, S. T. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.022 · Cited by 207

To engraft or not to engraft: an ecological framework for gut microbiome modulation with live microbes

Walter, J., Maldonado-Gómez, M. X., & Martínez, I. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.08.008 · Cited by 203

Multiple Binding Sites on the Pyrin Domain of ASC Protein Allow Self-association and Interaction with NLRP3 Protein

Vajjhala, P. R., Mirams, R. E., & Hill, J. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.381228 · Cited by 205

Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition

Rodriguez, G. A., Tai, L. M., LaDu, M. J., & Rebeck, G. W. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-111 · Cited by 193

The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment

Rojas, D. C. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1216-0 · Cited by 195

Mitigating risk in academic preclinical drug discovery

Dahlin, J. L., Inglese, J., & Walters, M. A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4578 · Cited by 192

Biomarkers in autism spectrum disorder: the old and the new

Ruggeri, B., Sarkans, U., Schumann, G., & Persico, A. M. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3290-7 · Cited by 199

CGG repeat in the FMR1 gene: size matters

Willemsen, R., Levenga, J., & Oostra, B. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01723.x · Cited by 184

Histopathologic characterization of the BTBR mouse model of autistic-like behavior reveals selective changes in neurodevelopmental proteins and adult hippocampal neurogenesis

Stephenson, D. T., O'Neill, S. M., Narayan, S., Tiwari, A., Arnold, E., Samaroo, H. D., Du, F., Ring, R. H., Campbell, B., Pletcher, M., et al. (2011) · Molecular Autism · doi:10.1186/2040-2392-2-7 · Cited by 180

Fragile X Syndrome: The GABAergic System and Circuit Dysfunction

Paluszkiewicz, S. M., Martin, B. S., & Huntsman, M. M. (2011) · Developmental Neuroscience · doi:10.1159/000329420 · Cited by 185

Characterizing immune repertoires by high throughput sequencing: strategies and applications

Calis, J. J. A., & Rosenberg, B. R. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.09.004 · Cited by 190

Psychometric Study of the Aberrant Behavior Checklist in Fragile X Syndrome and Implications for Targeted Treatment

Sansone, S. M., Widaman, K. F., Hall, S. S., Reiss, A. L., Lightbody, A. A., Kaufmann, W. E., Berry‐Kravis, E., Lachiewicz, A. M., Brown, E. C., & Hessl, D. R. (2011) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-011-1370-2 · Cited by 182

Translating Glutamate: From Pathophysiology to Treatment

Javitt, D. C., Schoepp, D., Kalivas, P. W., Volkow, N. D., Zarate, C., Merchant, K., Bear, M. F., Umbricht, D., Hajos, M., Potter, W. Z., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002804 · Cited by 168

Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu 5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile)

Christopher, J. A., Aves, S. J., Bennett, K. A., Dore, A. S., Errey, J. C., Jazayeri, A., Marshall, F. H., Okrasa, K., Serrano‐Vega, M. J., Tehan, B. G., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00892 · Cited by 166

Cognitive Dysfunctions in Intellectual Disabilities: The Contributions of the Ras-MAPK and PI3K-AKT-mTOR Pathways

Borrie, S. C., Brems, H., Legius, E., & Bagni, C. (2017) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091416-035332 · Cited by 169

Next-Generation Treatments for Mental Disorders

Insel, T. R. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004873 · Cited by 164

Fragile X syndrome

McLennan, Y., Polussa, J., Tassone, F., & Hagerman, R. (2011) · Current Genomics · doi:10.2174/138920211795677886 · Cited by 160

Gold nanoparticles as computerized tomography (CT) contrast agents

Xi, D., Dong, S., Meng, X., Lu, Q., Meng, L., & Ye, J. (2012) · RSC Advances · doi:10.1039/c2ra21263c · Cited by 163

Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation

Cosio, F. G., & Cattran, D. C. (2016) · Kidney International · doi:10.1016/j.kint.2016.08.030 · Cited by 158

Updated report on tools to measure outcomes of clinical trials in fragile X syndrome

Budimirovic, D. B., Berry‐Kravis, E., Erickson, C. A., Hall, S. S., Hessl, D. R., Reiss, A. L., King, M. K., Abbeduto, L., & Kaufmann, W. E. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9193-x · Cited by 159

Outcome Measures for Clinical Trials in Fragile X Syndrome

Berry‐Kravis, E., Hessl, D. R., Abbeduto, L., Reiss, A. L., Beckel-Mitchener, A. C., & Urv, T. K. (2013) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e31829d1f20 · Cited by 156

Fragile X targeted pharmacotherapy: lessons learned and future directions

Erickson, C. A., Davenport, M. H., Schaefer, T. L., Wink, L. K., Pedapati, E. V., Sweeney, J. A., Fitzpatrick, S. E., Brown, W. T., Budimirovic, D. B., Hagerman, R. J., et al. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9186-9 · Cited by 157

Design and implementation of adoptive therapy with chimeric antigen receptor‐modified T cells

Jensen, M. C., & Riddell, S. R. (2013) · Immunological Reviews · doi:10.1111/imr.12139 · Cited by 156

Towards more effective advanced drug delivery systems1

Crommelin, D. J. A., & Florence, A. T. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.02.020 · Cited by 158

PEGylation and polyPEGylation of nanodiamond

Zhang, X., Fu, C., Feng, L., Ji, Y. J., Tao, L., Huang, Q., Li, S., & Wei, Y. (2012) · Polymer · doi:10.1016/j.polymer.2012.05.029 · Cited by 151

Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self‐DNA

Lande, R., Chamilos, G., Ganguly, D., Demaria, O., Frasca, L., Durr, S., Conrad, C., Schröder, J., & Gilliet, M. F. (2014) · European Journal of Immunology · doi:10.1002/eji.201344277 · Cited by 157

Human umbilical cord mesenchymal stem cells transplantation improves cognitive function in Alzheimer’s disease mice by decreasing oxidative stress and promoting hippocampal neurogenesis

Cui, Y., Ma, S., Zhang, C., Cao, W., Liu, M., Li, D., Lv, P., Xing, Q., Qu, R., Yao, N., et al. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.12.021 · Cited by 152

A Folate Receptor-Targeting Nanoparticle Minimizes Drug Resistance in a Human Cancer Model

Wang, X., Li, J., Wang, Y., Koenig, L., Gjyrezi, A., Giannakakou, P., Shin, E. H., Tighiouart, M., Chen, Z. (., Nie, S., et al. (2011) · ACS Nano · doi:10.1021/nn200739q · Cited by 145

Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-Mediated drug resistance

Zeng, X., Morgenstern, R., & Nyström, A. M. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.042 · Cited by 135

Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results

FragXis Study Group, Youssef, E. A., Berry-Kravis, E., Czech, C., Hagerman, R. J., Hessl, D., Wong, C. Y., Rabbia, M., Deptula, D., John, A., et al. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.177 · Cited by 133

Talent Research in Sport 1990–2018: A Scoping Review

Baker, J. R., Wilson, S., Johnston, K., Dehghansai, N., Koenigsberg, A., de Vegt, S., & Wattie, N. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2020.607710 · Cited by 134

The NIH Toolbox Cognitive Battery for intellectual disabilities: Three preliminary studies and future directions

Hessl, D., Sansone, S. M., Berry-Kravis, E., Riley, K., Widaman, K. F., Abbeduto, L., Schneider, A., Coleman, J., Oaklander, D., Rhodes, K. C., et al. (2016) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-016-9167-4 · Cited by 126

Networking in Autism: Leveraging Genetic, Biomarker and Model System Findings in the Search for New Treatments

Veenstra-VanderWeele, J., & Blakely, R. D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.185 · Cited by 128

Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases

Campochiaro, P. A., & Akhlaq, A. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100921 · Cited by 130

The challenges of clinical trials in fragile X syndrome

Jacquemont, S., Berry‐Kravis, E., Hagerman, R. J., von Raison, F., Gasparini, F., Apostol, G., Ufer, M., Portes, V. D., & Gomez‐Mancilla, B. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3289-0 · Cited by 131

Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case–control study

Cremolini, C., Morano, F., Moretto, R., Berenato, R., Tamborini, E., Perrone, F., Rossini, D., Gloghini, A., Busico, A., Zucchelli, G., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx546 · Cited by 126

Of Men and Mice: Modeling the Fragile X Syndrome

Dahlhaus, R. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00041 · Cited by 133

The Matthew Effect and widely prescribed pharmaceuticals lacking environmental monitoring: Case study of an exposure-assessment vulnerability

Daughton, C. G. (2013) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2013.06.111 · Cited by 125

PEGylated nanodiamond for chemotherapeutic drug delivery

Wang, D., Tong, Y., Li, Y., Tian, Z., Cao, R., & Yang, B. (2013) · Diamond and Related Materials · doi:10.1016/j.diamond.2013.04.002 · Cited by 116

mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants

Chaki, S., Ago, Y., Pałucha-Poniewiera, A., Matrisciano, F., & Pilc, A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.022 · Cited by 116

Pharmacotherapy for the Core Symptoms in Autistic Disorder: Current Status of the Research

Farmer, C., Thurm, A. E., & Grant, P. (2013) · Drugs · doi:10.1007/s40265-013-0021-7 · Cited by 120

Relationship among Glutamine, γ-Aminobutyric Acid, and Social Cognition in Autism Spectrum Disorders

Cochran, D., Şıkoğlu, E. M., Hodge, S. M., Edden, R. A. E., Foley, A., Kennedy, D. N., Moore, C. M., & Frazier, J. A. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0112 · Cited by 120

Dendrimer space concept for innovative nanomedicine: A futuristic vision for medicinal chemistry

Mignani, S. M., Kazzouli, S. E., Bousmina, M., & Majoral, J. (2013) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2013.03.003 · Cited by 114

Ergocalciferol and Cholecalciferol in CKD

Nigwekar, S. U., Bhan, I., & Thadhani, R. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.12.035 · Cited by 115

Glycogen Synthase Kinase-3 Inhibitors Reverse Deficits in Long-term Potentiation and Cognition in Fragile X Mice

Franklin, A. V., King, M. K., Palomo, V., Martı́nez, A., McMahon, L. L., & Jope, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.003 · Cited by 113

Antiadhesion Therapy for Urinary Tract Infections—A Balanced PK/PD Profile Proved To Be Key for Success

Jiang, X., Abgottspon, D., Kleeb, S., Rabbani, S., Scharenberg, M., Wittwer, M., Haug, M. C., Schwardt, O., & Ernst, B. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300192x · Cited by 114

PolyPEGylated nanodiamond for intracellular delivery of a chemotherapeutic drug

Zhang, X., Wang, S., Fu, C., Feng, L., Ji, Y. J., Tao, L., Li, S., & Wei, Y. (2012) · Polymer Chemistry · doi:10.1039/c2py20457f · Cited by 110

A Cell-Based Framework for Numerical Modeling of Electrical Conduction in Cardiac Tissue

Tveito, A., Jæger, K. H., Kuchta, M., Mardal, K., & Rognes, M. E. (2017) · Frontiers in Physics · doi:10.3389/fphy.2017.00048 · Cited by 106

Electrocortical changes associated with minocycline treatment in fragile X syndrome

Schneider, A., Leigh, M. J., Adams, P., Nanakul, R., Chechi, T., Olichney, J., Hagerman, R., & Hessl, D. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113494105 · Cited by 108

Drug discovery for autism spectrum disorder: challenges and opportunities

Ghosh, A., Michalon, A., Lindemann, L., Fontoura, P., & Santarelli, L. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4102 · Cited by 108

Fragile X-associated disorders: a clinical overview

Gallagher, A. T., & Hallahan, B. P. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6161-3 · Cited by 116

Cyclodextrins in drug delivery: applications in gene and combination therapy

Haley, R. M., Gottardi, R., Langer, R., & Mitchell, M. J. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00724-5 · Cited by 114

Sensitive time-windows for susceptibility in neurodevelopmental disorders

Meredith, R. M., Dawitz, J., & Kramvis, I. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.03.005 · Cited by 109

Mediation of vertebrate life historiesviainsulin‐like growth factor‐1

Dantzer, B., & Swanson, E. M. (2011) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/j.1469-185x.2011.00204.x · Cited by 110

Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back

Gross, C., Hoffmann, A., Bassell, G. J., & Berry-Kravis, E. M. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0355-9 · Cited by 105

Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome

Scharf, S. H., Jaeschke, G., Wettstein, J. G., & Lindemann, L. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.004 · Cited by 106

Therapeutic Strategies in Fragile X Syndrome: Dysregulated mGluR Signaling and Beyond

Groß, C., Berry‐Kravis, E., & Bassell, G. J. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.137 · Cited by 109

Fragile X Syndrome and Targeted Treatment Trials

Hagerman, R. J., Lauterborn, J. C., Au, J., & Berry‐Kravis, E. (2011) · Results and problems in cell differentiation · doi:10.1007/978-3-642-21649-7_17 · Cited by 111

Targeted treatments for fragile X syndrome

Berry‐Kravis, E., Knox, A. T., & Hervey, C. (2011) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-011-9074-7 · Cited by 108

Fragile X syndrome: From protein function to therapy

Bagni, C., & Oostra, B. A. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36241 · Cited by 110

Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study

Bailey, D. B., Berry‐Kravis, E., Wheeler, A., Raspa, M., Merrien, F., Ricart, J., Koumaras, B., Rosenkranz, G., Tomlinson, M., von Raison, F., et al. (2015) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-015-9134-5 · Cited by 103

Epigenetic modification of the FMR1 gene in fragile X patients leads to a differential response to the mGluR5 antagonist AFQ056

Jacquemont, S., Curie, A., Portes, V. D., Torrioli, M. G., Berry‐Kravis, E., Hageman, R., Ramos, F. J., Cornish, K. M., He, Y., & neri, G. (2011) · Cited by 2

The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro

Tabolacci, E., Pirozzi, F., Gomez‐Mancilla, B., Gasparini, F., & Neri, G. (2012) · BMC Medical Genetics · doi:10.1186/1471-2350-13-13 · Cited by 15

Progress toward therapeutic potential for AFQ056 in Fragile X syndrome

Doering, L. C., Sourial, M. M., & Cheng, C. (2013) · Journal of Experimental Pharmacology · doi:10.2147/jep.s27044 · Cited by 8

mGlu5 as a potential therapeutic target for the treatment of fragile X syndrome

Robertson, L. (2013) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzt001 · Cited by 1

Fragile X syndrome therapy: to respond or not to respond may be a matter of methylation

Pouladi, M. A. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01663.x · Cited by 1